14802-10-9

Basic information

• Product Name: BENZENAMINE, 4-[2-(4-METHOXYPHENYL)ETHYL]-
• Synonyms: 4-[2-(4-METHOXYPHENYL)ETHYL]-BENZENAMINE;BENZENAMINE, 4-[2-(4-METHOXYPHENYL)ETHYL]-;4-[2-(4-methoxyphenyl)ethyl]aniline
• CAS NO: 14802-10-9
• Molecular Formula: C₁₅H₁₇NO
• Molecular Weight: 227.305
• Mol File: 14802-10-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BENZENAMINE, 4-[2-(4-METHOXYPHENYL)ETHYL]-(CAS DataBase Reference)
• NIST Chemistry Reference: BENZENAMINE, 4-[2-(4-METHOXYPHENYL)ETHYL]-(14802-10-9)
• EPA Substance Registry System: BENZENAMINE, 4-[2-(4-METHOXYPHENYL)ETHYL]-(14802-10-9)

Safety Data

• Hazardous Substances Data: 14802-10-9(Hazardous Substances Data)

Upstream product

• 104-03-0 4-nitrobenzeneacetic acid 
• 824-94-2 p-methoxybenzyl chloride 
• 3462-97-3 (4-methoxybenzyl)triphenylphosphonium bromide 
• 123-11-5 4-methoxy-benzaldehyde 
• 1472-68-0 1-methoxy-4-[2-(4-nitrophenyl)ethenyl]benzene 
• 4648-33-3 (E)-1-methoxy-4-(4-nitrostyryl)benzene 

Downstream Products

• 1259938-76-5 C₂₃H₁₈N₂O₅ 
• 1259938-77-6 C₂₃H₁₈N₂O₅ 
• 1186335-71-6 4,5,6,7-tetrachloro-2-(4-(4-methoxyphenethyl)phenyl)isoindoline-1,3-dione 
• 1186335-62-5 N-{4-[2-(4-methoxyphenyl)ethyl]phenyl}phthalimide 
• 14987-61-2 1-methoxy-4-(4-nitrophenethyl)benzene 
• 33384-05-3 4-(4-aminophenethyl)phenol 

Relevant articles and documents

Development of Tetrachlorophthalimides as Liver X Receptor β (LXRβ)-Selective Agonists

Liver X receptor (LXR) agonists are candidates for the treatment of atherosclerosis via induction of ABCA1 (ATP-binding cassette A1) gene expression, which contributes to reverse cholesterol transport (RCT) and to cholesterol efflux from the liver and intestine. However, LXR agonists also induce genes involved in lipogenesis, such as SREBP-1c (sterol regulatory binding element protein 1c) and FAS (fatty acid synthase), thereby causing an undesirable increase in plasma and hepatic triglyceride (TG) levels. Recent studies indicate that LXRα contributes to lipogenesis in liver, and selective LXRβ activation improves RCT in mice. Therefore, LXRβ-selective agonists are promising candidates to improve atherosclerosis without increasing plasma or hepatic TG levels. However, the ligand-binding domains in the two LXR isoforms α/β share high sequence identity, and few LXR ligands show subtype selectivity. In this study we identified a tetrachlorophthalimide analogue as an LXRβ-selective agonist. Structural development led to (E)-4,5,6,7-tetrachloro-2-(2-styrylphenyl)isoindoline-1,3-dione (24 a), which shows potent and selective LXRβ agonistic activity in reporter gene assays. In binding assays, compound 24 a bound to LXRβ preferentially over LXRα. It also induced the expression of ABCA1 mRNA but not SREBP-1c mRNA in cells. Compound 24 a appears to be a promising lead compound for therapeutic agents to treat atherosclerosis without the side effects induced by LXRα/β dual agonists.

Design and synthesis of phthalimide-based fluorescent liver X receptor antagonists

Based on our structure-activity relationship study of liver X receptor (LXR) ligands, we designed and synthesized fluorescent LXR antagonists containing an unsubstituted or substituted amino group on a phthalimide unit.

The synthesis and structure-activity relationship of substituted N-phenyl anthranilic acid analogs as amyloid aggregation inhibitors

It is believed that β-amyloid aggregation is an important event in the development of Alzheimer's disease. In the course of our studies to identify β-amyloid aggregation inhibitors, a series of N-phenyl anthranilic acid analogs were synthesized and studied for β-amyloid inhibition activity. The synthesis, structure-activity relationship, and in vivo activity of these analogs are discussed.